These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 32135398)
1. Individual and network factors associated with HCV treatment uptake among people who inject drugs. Falade-Nwulia O; Sacamano P; McCormick SD; Yang C; Kirk G; Thomas D; Sulkowski M; Latkin C; Mehta SH Int J Drug Policy; 2020 Apr; 78():102714. PubMed ID: 32135398 [TBL] [Abstract][Full Text] [Related]
2. Role of direct and indirect social and spatial ties in the diffusion of HIV and HCV among people who inject drugs: a cross-sectional community-based network analysis in New Delhi, India. Clipman SJ; Mehta SH; Srikrishnan AK; Zook KJ; Duggal P; Mohapatra S; Shanmugam S; Nandagopal P; Kumar MS; Ogburn E; Lucas GM; Latkin CA; Solomon SS Elife; 2021 Aug; 10():. PubMed ID: 34342266 [TBL] [Abstract][Full Text] [Related]
3. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era. Falade-Nwulia O; Gicquelais RE; Astemborski J; McCormick SD; Kirk G; Sulkowski M; Thomas DL; Mehta SH Liver Int; 2020 Oct; 40(10):2407-2416. PubMed ID: 32770638 [TBL] [Abstract][Full Text] [Related]
4. Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study. McFall AM; Solomon SS; Lucas GM; Celentano DD; Srikrishnan AK; Kumar MS; Mehta SH Addiction; 2017 Aug; 112(8):1480-1487. PubMed ID: 28317210 [TBL] [Abstract][Full Text] [Related]
5. Respondent-driven sampling for identification of HIV- and HCV-infected people who inject drugs and men who have sex with men in India: A cross-sectional, community-based analysis. Solomon SS; McFall AM; Lucas GM; Srikrishnan AK; Kumar MS; Anand S; Quinn TC; Celentano DD; Mehta SH PLoS Med; 2017 Nov; 14(11):e1002460. PubMed ID: 29182638 [TBL] [Abstract][Full Text] [Related]
6. Drug use stigma and its association with active hepatitis C virus infection and injection drug use behaviors among community-based people who inject drugs in India. Patel EU; Solomon SS; Lucas GM; McFall AM; Tomori C; Srikrishnan AK; Kumar MS; Laeyendecker O; Celentano DD; Thomas DL; Quinn TC; Mehta SH Int J Drug Policy; 2021 Oct; 96():103354. PubMed ID: 34247900 [TBL] [Abstract][Full Text] [Related]
7. Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland: A quantitative cross-sectional analysis. Yuan JM; Croxford S; Viviani L; Emanuel E; Phipps E; Desai M Int J Drug Policy; 2022 Nov; 109():103821. PubMed ID: 35994940 [TBL] [Abstract][Full Text] [Related]
8. Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration. Ward KM; McCormick SD; Sulkowski M; Latkin C; Chander G; Falade-Nwulia O Int J Drug Policy; 2021 Feb; 88():103019. PubMed ID: 33160152 [TBL] [Abstract][Full Text] [Related]
9. Risky injection practices and HCV awareness in Chiang Mai Province, Thailand: a respondent-driven sampling study of people who inject drugs. Prouté M; Le Coeur S; Tiv MH; Dub T; Jongpaijitsakul P; Ratnamhin A; Angkurawaranon C; Aramrattana A; Lallemant M BMC Public Health; 2020 Sep; 20(1):1450. PubMed ID: 32972359 [TBL] [Abstract][Full Text] [Related]
10. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington. Corcorran MA; Tsui JI; Scott JD; Dombrowski JC; Glick SN Drug Alcohol Depend; 2021 Mar; 220():108525. PubMed ID: 33461152 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California. Ozga JE; Syvertsen JL; Pollini RA J Viral Hepat; 2022 Jul; 29(7):518-528. PubMed ID: 35357738 [TBL] [Abstract][Full Text] [Related]
12. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. Falade-Nwulia O; Irvin R; Merkow A; Sulkowski M; Niculescu A; Olsen Y; Stoller K; Thomas DL; Latkin C; Mehta SH J Subst Abuse Treat; 2019 May; 100():45-51. PubMed ID: 30898327 [TBL] [Abstract][Full Text] [Related]
13. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB; Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989 [TBL] [Abstract][Full Text] [Related]
14. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique. Semá Baltazar C; Horth R; Boothe M; Sathane I; Young P; Chitsondzo Langa D; Condula M; Ricardo H; Dengo Baloi L; Cummings B; Schaad N; Gouveia L; Teodoro E; Raymond HF BMC Infect Dis; 2019 Dec; 19(1):1022. PubMed ID: 31791273 [TBL] [Abstract][Full Text] [Related]
15. Characteristics associated with HIV and hepatitis C seroprevalence among sexual and injecting partners of HIV positive persons who inject drugs in Nairobi and coastal Kenya. Sambai BC; Kingston H; Monroe-Wise A; Mbogo L; Juma E; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Scott J; Bosire R; Dunbar M; Macharia P; Masyuko S; Sinkele W; Herbeck JT; Farquhar C BMC Infect Dis; 2022 Jan; 22(1):73. PubMed ID: 35062890 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of HIV, viral hepatitis B/C and tuberculosis and treatment outcomes among people who use drugs: Results from the implementation of the first drop-in-center in Mozambique. Semá Baltazar C; Kellogg TA; Boothe M; Loarec A; de Abreu E; Condula M; Fazito E; Raymond HF; Temmerman M; Luchters S Int J Drug Policy; 2021 Apr; 90():103095. PubMed ID: 33429163 [TBL] [Abstract][Full Text] [Related]
17. Age-Related Differences in Past or Present Hepatitis C Virus Infection Among People Who Inject Drugs: National Human Immunodeficiency Virus Behavioral Surveillance, 8 US Cities, 2015. Abara WE; Trujillo L; Broz D; Finlayson T; Teshale E; Paz-Bailey G; Glick S; Al-Tayyib AA; Robinson WT; Masiello-Schuette S; Sey EK; Anderson BJ; Poe J; Braunstein S J Infect Dis; 2019 Jul; 220(3):377-385. PubMed ID: 30915477 [TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus prevalence, determinants, and cascade of care among people who inject drugs in Iran. Khezri M; Mirzazadeh A; Shokoohi M; Sharafi H; Ghalekhani N; Tavakoli F; Mehmandoost S; Mousavian G; Imani M; Kakavand-Ghalehnoei R; Komasi A; Gouya MM; Haghdoost AA; McFarland W; Karamouzian M; Sharifi H Drug Alcohol Depend; 2023 Feb; 243():109751. PubMed ID: 36621200 [TBL] [Abstract][Full Text] [Related]
19. High-Risk Injection-Related Practices Associated with anti-HCV Positivity among Young Adults Seeking Services in Three Small Cities in Wisconsin. Rogers-Brown J; Sublett F; Canary L; Rein DB; Bhat M; Thompson WW; Vellozzi C; Asher A Subst Use Misuse; 2022; 57(5):665-673. PubMed ID: 35240921 [TBL] [Abstract][Full Text] [Related]
20. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study. Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]